AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie contingent Consideration Liability — Total Level 3 Fair Value ($M) ($M)
Form 10-Q / 10-K Financial Instruments & Fair Value Measurements Note
Latest, FY2025
25,374
Period ended Dec 31, 2025
Change on a year earlier
+17.1%
21,666 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent Consideration Liability — Total Level 3 Fair Value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25,374 | +17.1% | Form 10-Q (filed 2026-08-03) ↗ |
| FY2024 | Dec 31, 2024 | 21,666 | +8.9% | Form 10-Q (filed 2026-08-03) ↗ |
| FY2023 | Dec 31, 2023 | 19,890 | +21.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 16,384 | +10.1% | Form 10-K (filed 2026-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 14,887 | +14.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 12,997 | +77.1% | Form 10-K (filed 2024-02-20) ↗ |
| FY2019 | Dec 31, 2019 | 7,340 | +63.7% | Form 10-K (filed 2023-02-17) ↗ |
| FY2018 | Dec 31, 2018 | 4,483 | -1.1% | Form 10-K (filed 2022-02-18) ↗ |
| FY2017 | Dec 31, 2017 | 4,534 | +7.6% | Form 10-K (filed 2021-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 4,213 | – | Form 10-K (filed 2020-02-21) ↗ |
| FY2015 | Dec 31, 2015 | 0 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up contingent consideration liability — total level 3 fair value ($m)
- Contingent Consideration Liability — Noncurrent Portion [year-end] ($M)21,919 · FY2025
- Contingent Consideration Liability — Current Portion [year-end] ($M)3,455 · FY2025
- Level 3 Rollforward — Additions ($M)78 · FY2025
- Level 3 Rollforward — Change in Fair Value Recognized in Earnings ($M)6,495 · FY2025
- Level 3 Rollforward — Cash Settlements and Payments ($M)2,865 · FY2025
- Valuation Inputs — Discount Rate Minimum (%)4.8% · FY2025
- Valuation Inputs — Discount Rate Maximum (%)3.7% · FY2025
- Valuation Inputs — Discount Rate Weighted Average (%)4.0% · FY2025
- Valuation Inputs — Payment Probability Maximum (%)100.0% · FY2025
- Valuation Inputs — Payment Probability Weighted Average (%)100.0% · FY2025
Cite this data
StockData. (2026). AbbVie Contingent Consideration Liability — Total Level 3 Fair Value ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc_liab_tot
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.